|
Apricitabine (INN, codenamed AVX754 and SPD754, sometimes abbreviated to ATC) is an experimental nucleoside reverse transcriptase inhibitor (NRTI) against HIV. It is structurally related to lamivudine and emtricitabine, and, like these, is an analogue of cytidine. ==History== It was first developed by BioChem Pharma (where it was called BCH10618). BioChem Pharma was then sold to Shire Pharmaceuticals (where apricitabine was called SPD754). Shire then sold the rights to develop the drug to Avexa Pharmaceuticals, an Australian pharmaceutical company.〔(AIDSmeds.com - apricitabine )〕 , apricitabine has closed its phase III clinical trial,〔''(Avexa Closes ATC's Phase III Trial To Evaluate Data )''〕 and has been granted fast track status by the United States Food and Drug Administration. Avexa announced its decision to end work on apricitabine in May 2010, which Avexa spent more than A$100 million ($90 million) developing and was in the final of three stages of patient studies usually needed for U.S. regulatory approval. Grounds for the shutdown included the inability to find commercial partners for global licensing, concerns about legal protections of the drug in the US market, and difficulty confirming the effectiveness of the drug in patients where other retroviral drugs masked key indicators.〔Avexa Company Announcement: (Avexa closes apricitabine (ATC) program )〕 In March 2011 it was announced by the company to the Australian Stock Exchange that the FDA had agreed that a new, shorter, single Phase III trial design, including about 300 patients dosed for 2 weeks, was required before approval. A similar agreement with the EMA was announced in March 2012.〔Avexa: (Avexa and FDA agree path forward for ATC )〕 In November 2011 the company sought to extend its patents over apricitabine and was in discussions for fast-track approval with European regulators. The company also indicated that clinical trials had shown better-than-expected results from simultaneous provision of the drug alongside two other marketed drugs when compared to those drugs with lamivudine, another NRTI.〔Avexa Company Announcement to Australian Stock Exchange: (Avexa files to extend ATC patent life )〕 Avexa's latest update in 2013 reported that the drug was still in phase IIb trials and had not yet started phase III. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Apricitabine」の詳細全文を読む スポンサード リンク
|